Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17”In the company’s words, NCT05170269 on ClinicalTrials.gov
- Tested for
- Congenital Cytomegalovirus Infection
- Main trialPhase 3
- “A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection. The main purpose of the trial is to demonstrate efficacy and safety of Cytotect CP Biotest in preventing maternal-fetal transmission of cytomegalovirus (CMV).”In the company’s words, NCT05170269 on ClinicalTrials.gov
Other drugs for Congenital Cytomegalovirus Infection
- MRNA-1647Moderna · Phase 2
- LB-DTK-MVLucasBio · Phase 1/2
- ArtesunateAmivas Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 19 Nov 2023 | Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026